It is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer [ 42].
Prostate-specific antigen (PSA), a well-known tumor marker for prostate cancer (PCa), has been found complexed with IgM in both benign prostatic hyperplasia (BPH) and cancer [ 3].
Improving the P.S.A.? Experts generally agree that the P.S.A. is not an ideal marker for prostate cancer.
Men who take a drug to reduce hair loss may also be reducing their levels of P.S.A., a marker for prostate cancer.
The PSA (prostate-specific antigen) is generally known to be a marker for prostate cancer.
The speed at which a marker for prostate cancer grows is a strong indicator for how much risk a patient runs, even if the level is so low that a biopsy ordinarily would not be ordered, researchers have found.
Prostate specific antigen (PSA) is a widely used and clinically valuable marker for prostate disease.
Annexin A3 (ANXA3) is a potential marker for prostate cancer (PCa).
Prostate-specific membrane antigen (PSMA; also known as glutamate carboxypeptidase II (GPCII)) is a well-established marker for prostate carcinoma.
Prostate-specific membrane antigen (PSMA) is a well-established marker for prostate carcinoma with increased levels of expression in high-grade, hormone-refractory and metastatic disease.
The scAb construct enhanced expression levels significantly, facilitating antibody screening and immunoassay development for prostate-specific antigen (PSA), a marker for prostate cancer.
